Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 1, 2006, Pages 131-137

  Lemoine, Patrick ^a   Kermadi, Imane ^b   Garcia Acosta, Stéphanie ^b   Garay, Ricardo P ^c,d   Dib, Michel ^b  

^a Unité Clinique de Psychiatrie Biologique Le Vinatier   (France)

^b SANOFI   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NONE   (France)

Author keywords

Anxiety; Benzodiazepine; Cyamemazine; Drug substitution; Withdrawal

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BROMAZEPAM; CYAMEMAZINE; LORAZEPAM; OXAZEPAM; PLACEBO;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HAMILTON ANXIETY SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REBOUND; RECURRENT DISEASE; SOMNOLENCE; STATISTICAL SIGNIFICANCE; THORAX PAIN; VERTIGO; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BENZODIAZEPINES; BROMAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GABA MODULATORS; HUMANS; MALE; MIDDLE AGED; PERSONALITY INVENTORY; PHENOTHIAZINES; PSYCHIATRIC STATUS RATING SCALES; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

EID: 29644444311     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.08.015     Document Type: Article

References (35)

1. D. Ajzenberg Utilisation d'un nouveau neuroleptique sédatif, la cyamémazine (Tercian®) dans l'alcoolisme Psychol. Méd. 5 1973 5 6
2. 2C-receptor antagonist properties of cyamemazine: significance for its clinical anxiolytic activity Psychopharmacology 147 2000 412 417
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed. 1994 APA Washington, DC DSM-IV
4. N. Andrews, and S.E. File Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence Psychopharmacologia (Berl) 112 1993 21 25
5. C.H. Ashton, M.D. Rawlins, and S.P. Tyrer A double blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users Br. J. Psychiatry 157 1990 232 238
6. I. Bobolakis Neuroleptic malignant syndrome following tiapride treatment of clonazepam withdrawal Eur. Psychiatr. 10 1995 110 111
7. M. Bourin, B.A.N. Dhonnchadha, M.C. Colombel, M. Dib, and M. Hascoët Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice Behav. Brain Res. 124 2001 87 95
8. Declaration of Helsinki, Hong Kong amendment (September 1989).
9. European Forum for Good Clinical Practice. "European Guidelinesnext term for Auditing Independent Ethics Committees." 2001. Available from: URL: http://www.efgcp.org.
10. C. Gury, F. Berchot, C..Fabre, J. Surugue, and N. Welcomme Analyse des prescriptions de neuroleptiques dans cinq centres hospitaliers spécialisés. Comparaisons entre prescriptions hospitalières et prescriptions de sortie Inf. Psychiatr. 76 2000 954 963
11. A. Hameg, F. Bayle, P. Nuss, P. Dupuis, R.P. Garay, and M. Dib Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes Biochem. Pharmacol. 65 2003 435 440
12. M. Hamilton The assessment of anxiety state by rating Br. J. Med. Psychiatr. 32 1959 50 55
13. B.J. Kaminski, C.A. Sannerud, E.M. Weerts, R.J. Lamb, and R.R. Griffiths Physical dependence in baboons chronically treated with low and high doses of diazepam Behav. Pharmacol. 14 2003 331 342
14. C.C. Kan, S.R. Hilberink, and M.H. Breteler Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach Compr. Psychiatry 45 2004 88 94
15. J.M. Keppel Hesselink Promising anxiolytics? A new class of drugs: the azapirones S.M. Stahl M. Gastpar J.M. Keppel Hesselink J. Traber Serotonin1A Receptors in Depression and Anxiety 1992 Raven Press New York, NY 171 183
16. P. Lemoine, H. Allain, C. Janus, and P. Sutet Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months Eur. Psychiatr. 10 Suppl. 3 1995 161S 165S
17. L. Miller, D. Greenblatt, G. Barnhill, and R. Shader Chronic benzodiazepine administration: I. Tolerance is associated with benzodiazepine receptor down-regulation and decreased gamma-aminobutyric acid receptor function J. Pharmacol. Exp. Ther. 246 1988 170 176
18. M. Naassila, E. Legrand, F. d'Alché-Birée, and M. Daoust Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice Psychopharmacology 140 1998 421 428
19. J.S. New The discovery and development of buspirone: a new approach to the treatment of anxiety Med. Res. Rev. 10 1990 283 326
20. D.J. Nutt Selective ligands for benzodiazepine receptors: recent developments Curr. Asp. Neurosci. 2 1990 259 293
21. K.P. O'Connor, A. Marchand, L.B. Bélanger, N. Mainguy, P. Landry, P. Savard, J. Turcotte, G. Dupuis, F. Harel, and L. Lachance Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: a replication Addict. Behav. 29 2004 583 593
22. J.F. Pagel, and B.L. Parnes Medications for the treatment of sleep disorders: an overview Prim. Care Companion J. Clin. Psychiat. 3 2001 118 125
23. J. Peinado, A. Hameg, R.P. Garay, F. Bayle, P. Nuss, and M. Dib Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine Naunyn-Schmiedeberg's Arch. Pharmacol. 367 2003 134 139
24. M. Petrovic, D. Pevernagie, N. Van den Noortgate, A. Mariman, W. Michielsen, and M. Afschrift A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality Int. J. Geriatr. Psychiatry 14 1999 754 760
25. P. Pichot, P. Boyer, C.B. Pull, N. Reim, M. Simon, and A. Thibault Un questionnaire d'autoévaluation de la symptomatologie dépressive, le questionnaire QDZA. (QDZA. A self-administered questionnaire of depressive symptomatology) Rev. Psychol. Appl. 34 1984 323 340
26. J. Podhorna The experimental pharmacotherapy of benzodiazepine withdrawal Curr. Pharm. Des. 8 2002 23 44
27. D. Poyares, C. Guilleminault, M.M. Ohayon, and S. Tufik Chronic benzodiazepine usage and withdrawal in insomnia patients J. Psychiatr. Res. 38 2004 327 334
28. F. Radat Cyamémazine: traitement symptomatique des dimensions anxieuses, impulsives et agressives Inf. Psychiatr. 10 1995 967 968
29. K. Rickels, E. Schweitzer, G. Case, and D.J. Greenblatt Long-term therapeutic use of benzodiazepines: I. Effects of abrupt discontinuation Arch. Gen. Psychiatry 47 1990 899 907
30. P.P. Roy-Byrne, M.D. Sullivan, D.S. Cowley, and R.K. Ries Adjunctive treatment of benzodiazepine discontinuation syndromes: a review J. Psychiatr. Res. 27 Suppl. 1 1993 143 153
31. C.M. Shapiro, D. Sherman, and D.F. Peck Withdrawal from benzodiazepines by initially switching to zopiclone Eur. Psychiatr. 10 Suppl. 3 1995 145S 151S
32. E. Schweizer The pharmacological management of benzodiazepine withdrawal Eur. Neuropsychopharmacol. 6 1996 160
33. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 J. Clin. Psychiatry 59 Suppl. 20 1998 22 33
34. F.G. Zitman, and J.E. Couvee Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group Br. J. Psychiatry 178 2001 317 324
35. W. Zung A rating instrument for anxiety disorders Psychosomatics 12 1971 371 379